Loading...
CAR T‐Cell Therapy Shows Durable Responses in Indolent NHL
In an update from the ongoing phase II ZUMA‐5 trial, axicabtagene ciloleucel showed a high response rate and durable clinical benefit in patients with relapsed/refractory indolent non‐Hodgkin lymphoma, including follicular lymphoma and marginal zone lymphoma.
Na minha lista:
| Udgivet i: | Oncologist |
|---|---|
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
John Wiley & Sons, Inc.
2020
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7330923/ https://ncbi.nlm.nih.gov/pubmed/32588925 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1634/theoncologist.2020-0559 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|